Treatment of thalassaemia: a review of the new approaches on transfusion safety and the novel therapeutics

Lifetime red cell concentrate (RCC) transfusions still account for significant iron overload‐related morbidity and mortality despite chelation therapy in thalassaemia. The cumulative risk of transfusion‐transmitted infections is substantial for thalassaemia patients. Pathogen reduction technologies for RCC may imply a proactive approach against new/re‐emerging pathogens and may be an ultimate safeguard for transfusion safety in the developing countries. Red cell alloimmunization may become a significant clinical challenge in thalassaemia. The availability of high‐throughput molecular blood group antigen typing in the donors may allow perfect match transfusion, beyond ABO‐D and CEK antigen‐matched transfusions. Allogeneic stem cell transplantation (A‐SCT) is the only available curative therapy in thalassaemia, but carries a substantial risk of serious adverse events and mortality. Gene addition therapy for correction of the α‐globin chain imbalance overcomes the problems of donor availability and immunological complications of A‐SCT. Gene editing by either gene disruption or correction emerged as a potential alternative to gene addition therapy in beta‐thalassaemia. A new era of novel therapeutics targeting α/β imbalance, ineffective erythropoiesis or iron dysregulation is unfolding in thalassaemia management, and a number of those now have agents in preclinical and clinical development. Hydroxyurea (HU) may improve globin chain imbalance and be beneficial for reducing or omitting transfusion requirement. Ruxolitinib has allowed steady decrease in spleen volume that may serve for avoiding splenectomy in beta‐thalassaemia. Luspatercept may restore normal erythroid differentiation and improve anaemia. Hepcidin mimetics or TMPRSS6 inhibitors may modulate ineffective erythropoiesis by iron restriction and improve anaemia and organ iron loading.     

富亮氨酸胶质瘤失活1蛋白抗体阳性边缘性脑炎 临床分析及文献复习

目的：总结富亮氨酸胶质瘤失活1蛋白（LGI1）抗体阳性边缘性脑炎的临床和影像特点及诊疗预后。 方法：报道我院1例LGI1抗体阳性相关边缘性脑炎并文献复习。结果：患者女性，60岁，表现为渐进性加重 的记忆力减退、癫痫发作（全身强直阵挛发作，面-臂肌张力障碍发作）、低钠血症和轻度精神行为异常。颅 脑MRI-T2/Flair序列提示双侧颞叶（左侧为甚）内侧、海马异常高信号。脑脊液抗LGI1抗体阳性（++）。经激 素治疗症状有所改善。检索既往报道LGI1抗体阳性边缘性脑炎患者237例，多数呈急性、亚急性起病，最 常见是记忆障碍、癫痫（含面-臂肌张力障碍发作）和低钠血症，头颅MRI（特别是MRI-T2/Flair序列）显示单 侧或者双侧海马区、颞叶异常多见，早期免疫治疗预后良好。结论：LGI1抗体阳性相关边缘性脑炎有其特 有的临床特点，免疫治疗可明显改善患者预后。     

载氧血红蛋白纯化工艺研究

目的改善心脑血管缺氧载氧药物是一种创新药物。由于它半径比红细胞小400~1 000倍,易于通过毛细血管,给缺血组织及时供氧,迅速缓解或纠正缺氧状态,达到治疗抢救目的。血红蛋白的纯化工艺是载氧药物研制的重要工艺步骤。方法本研究建立了一套通过热敏法分离纯化人脐带血血红蛋白的工艺以及较为完善的纯化血红蛋白质量检测指标。结果与现有的纯化方式相比,热敏法操作简便,仪器设备造价低廉,纯化与病毒灭活同时进行,得到的纯化产品损失少,纯度高,各项理化指标达到国际水平。结论本工艺适用于规模制备纯化血红蛋白,为进一步研制治疗心脑血管缺氧载氧药物创造了有利条件。     

臭氧水对SARS病毒的灭活效果观察

为了观察电解法产生的臭氧水对SARS病毒的灭活效果,采用悬液灭活试验法进行了试验。结果,以臭氧含量为27.73mg/L,作用4min可完全灭活SARS病毒;以臭氧含量为17.82mg/L,作用4min和4.86mg/L作用10min,均可使SARS病毒的灭活率达100％。结论,电解法产生的臭氧水含臭氧量达到4.86mg/L以上,对悬液内SARS病毒具有很强的灭活效果。     

过氧戊二酸对大肠杆菌噬菌体f2杀灭机理

观察结果表明过氧戊二酸对大肠杆菌噬菌休ｆ２有较强的杀灭作用，并影响其吸附特性和感染能力。电镜观察表明过氧戊二酸处理后的ｆ２颗粒聚集成团、变形破碎或残缺不全，这可能是ｆ２灭活的主要原因。     

长链核酸扩增技术评价病毒灭活效果的研究

目的:探讨用长链核酸扩增技术评价病毒灭活效果的可行性.方法:针对伪狂犬病毒(pseudorabies virus,PRV)糖蛋白gD基因前后的保守区设计预计产物长短不一的5对引物,用半巢式PCR技术扩增经低pH法(4.0±0.1)、巴氏消毒法[(60±1.0)℃]和s/D法(有机溶剂/洗涤荆)处理后的PRV核酸,同时以细胞感染法做平行对照.结果:低pH对PRV核酸有破坏作用,处理时间越长,核酸损伤程度越明显,处理60 min时,6.62 lgTCID50的PRV完全被灭活.5条不同长度PCR扩增产物中,只有3.9 kb的长片段检出与细胞培养结果一致.7.25 lgTCID50的PRV经(60±1.0)℃处理20 min后即被完全灭活,7.13 lgTCID50的PRV经s/D法处理1 h后被完全灭活,但各长度核酸片段扩增均为阳性,与细胞感染试验结果不符.结论:低pH对PRV核酸的损伤程度随处理时间的延长而增加;用长链PCR(3.9 kb)技术来评价经低pH法灭活病毒的效果是可行的,而该法不适合评价巴氏消毒法和S/D法灭活病毒的效果.     

Immunoblotting human C4 bound to human erythrocytes in vivo and in vitro.

A study of C4 bound to human erythrocytes in vitro and in vivo has been made by immunoblotting with mouse monoclonal anti-C4c and anti-C4d and human polyclonal anti-C4d (Rodgers and Chido) following SDS-PAGE. Multi-banded patterns differentiated between C4A and C4B isotypes. Treatment of EC4b with trypsin eliminated immunoblotting but not agglutination reactions. Serum inactivation (factor I) of EC4b resulted in banding patterns similar to those obtained from patients' EC4d. Treatment of EC4b membranes with NH2OH affected many of the bands, two were lost, one was markedly reduced and others had altered SDS-PAGE mobility. Interpretation of the bands has been made in terms of C4-acceptor complexes and inactivation fragments of C4. A distinct difference in the banding of C4A and C4B isotypes has been detected.     

The Role of Horizontal Connections in Generating Long Receptive Fields in the Cat Visual Cortex

The cells in the primary visual cortex possess numerous functional properties that are more complex and varied than those seen in the cortical input. These properties result from the network of intrinsic cortical connections running across the cortical layers and between cortical columns. In the current study we relate the long receptive fields that are characteristic of layer 6 cells to the input that these cells receive from layer 5. The axons of layer 5 pyramidal cells project over long distances within layer 6, enabling layer 6 cells to collect input from regions of cortex representing large parts of the visual field. When layer 5 was locally inactivated by injection of the inhibitory transmitter GABA, layer 6 cells lost sensitivity over the portion of their receptive fields corresponding to the inactivated region of layer 5. This suggests that the extensive convergence in the projection from layer 5 to layer 6 is responsible for generating the long receptive fields characteristic of the layer 6 cells.     

Preaxial acrofacial dysostosis (Nager syndrome) associated with an inherited and apparently balanced X;9 translocation: Prenatal and postnatal late replication studies

We report on an infant with preaxial acrofacial dysostosis (Nager syndrome) who was diagnosed prenatally as having an apparently balanced X/autosome translocation [46,X,t(X;9)(p22.1;q32)mat] inherited from a previously diagnosed mosaic translocation carrier mother [46,XX/46,X,t(X;9)(p22.1;q32)]. Replication studies on amniocytes showed the normal X chromosome to be late replicating while the same studies repeated on the infant's lymphocytes showed the translocated X chromosome to be late replicating in most cells. Late replication studies of the mother's lymphocytes demonstrated that the normal X chromosome was late replicating in most cells. The presence of Nager syndrome in this infant may be the result of critical break-points and/or position effects on chromosome 9, inducing expression of a gene responsible for the syndrome. © 1993 Wiley-Liss, Inc.